SCHEMBL337888

SCHEMBL337888

CC(C)(C)OC(=O)NCc1ccnc(N)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.48
GABRP O00591 1/20 0.48
GABRD O14764 1/20 0.48
GABRA1 P14867 1/20 0.48
GABRB1 P18505 1/20 0.48
GABRG2 P18507 1/20 0.48
GABRB3 P28472 1/20 0.48
GABRA5 P31644 1/20 0.48
GABRA3 P34903 1/20 0.48
GABRA2 P47869 1/20 0.48
GABRB2 P47870 1/20 0.48
GABRA4 P48169 1/20 0.48
GABRE P78334 1/20 0.48
GABRA6 Q16445 1/20 0.48
GABRG1 Q8N1C3 1/20 0.48
GABRG3 Q99928 1/20 0.48
GABRQ Q9UN88 1/20 0.48
BRD4 O60885 1/20 0.46
NAMPT P43490 2/20 0.46
NOS3 P29474 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8117393 0.85 L3MBTL1 (0.47) L3MBTL1BRD4NAMPTGRM2HDAC1
SCHEMBL15871964 0.84 BRD4 (0.49) L3MBTL1BRD4NAMPTGRM2KDM4A
SCHEMBL30399922 0.84 L3MBTL1 (0.49) L3MBTL1BRD4NAMPTGRM2HDAC1
SCHEMBL10163771 0.84 L3MBTL1 (0.49) L3MBTL1BRD4NAMPTGRM2KDM4A
Hydrochloric Acid SCHEMBL29868035 0.84 L3MBTL1 (0.46) L3MBTL1BRD4NAMPTGRM2HDAC1
SCHEMBL5013602 0.84 GRM2 (0.53) L3MBTL1BRD4NAMPTGRM2KDM4A
SCHEMBL14200095 0.83 LMNA (0.52) L3MBTL1BRD4NAMPTGRM2KDM4A
SCHEMBL4896757 0.83 BRD4 (0.48) L3MBTL1BRD4NAMPTGRM2KDM4A
SCHEMBL13391259 0.83 L3MBTL1 (0.48) L3MBTL1BRD4NAMPTGRM2KDM4A
SCHEMBL30392761 0.83 L3MBTL1 (0.48) L3MBTL1BRD4NAMPTGRM2KDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3788039-B1 FACTOR XIIA INHIBITORS UNIV LEEDS INNOVATIONS LTD (GB) 2026-02-11 EP disclosed
US-11851446-B2 Probes for imaging Huntingtin protein CHDI FOUNDATION, INC. (US) 2023-12-26 US disclosed
EP-3197277-B1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION INC (US) 2021-12-22 EP disclosed
EP-3197277-B1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION INC (US) 2021-12-22 EP disclosed
US-20210380608-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. 2021-12-09 US disclosed
US-20210380608-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. 2021-12-09 US disclosed
CN-107105667-B Probes for imaging huntingtin CHDI基金会股份有限公司 2021-08-17 CN disclosed
US-20210087172-A1 FACTOR XIIa INHIBITORS UNIVERSITY OF LEEDS (GB) 2021-03-25 US disclosed
US-20210087172-A1 FACTOR XIIa INHIBITORS UNIVERSITY OF LEEDS (GB) 2021-03-25 US disclosed
EP-3788039-A1 FACTOR XIIA INHIBITORS University of Leeds (GB) 2021-03-10 EP disclosed
US-8097617-B2 Organic compounds NOVARTIS AG (CH) 2012-01-17 US disclosed
US-8097617-B2 Organic compounds NOVARTIS AG (CH) 2012-01-17 US disclosed
US-20110294777-A1 BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-12-01 US disclosed
US-20090253689-A1 Organic Compounds NOVARTIS AG (CH) 2009-10-08 US disclosed
US-20090253689-A1 Organic Compounds NOVARTIS AG (CH) 2009-10-08 US disclosed
US-20090253689-A1 Organic Compounds NOVARTIS AG (CH) 2009-10-08 US disclosed
EP-2004643-A1 ORGANIC COMPOUNDS Novartis AG (CH) 2008-12-24 EP disclosed
WO-2007113226-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-10-11 WO disclosed
WO-2007113226-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-10-11 WO disclosed
WO-2006128184-A2 PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS ALANTOS-PHARMACEUTICALS, INC. (US) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11851446-B2 Probes for imaging Huntingtin protein HTT, HYPK, HSPBP1 L3MBTL1 3337/4885GABRP 1555/4885GABRD 3170/4885
US-20110294777-A1 BETA-LACTAMASE INHIBITORS MGAM, RPIA, LBR L3MBTL1 745/4885GABRP 65/4885GABRD 347/4885
US-20210380608-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN HTT, HYPK, HSPBP1 L3MBTL1 3337/4885GABRP 1555/4885GABRD 3170/4885
US-20210087172-A1 FACTOR XIIa INHIBITORS F11, F13B, F12 L3MBTL1 3858/4885GABRP 1406/4885GABRD 4161/4885
US-20090253689-A1 Organic Compounds OAT, GPR119, OTC L3MBTL1 4046/4885GABRP 703/4885GABRD 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.